SCHEMBL4476071

SCHEMBL4476071

COc1cc2ncnc(Oc3ccc(NC(=O)NCCC(C)(C)C)cc3)c2cc1OC

nearest known ligand 0.78

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.78
PDGFRA P16234 3/20 0.73
CSF1R P07333 1/20 0.70
KIT P10721 2/20 0.64
PDGFRB P09619 2/20 0.64
FLT4 P35916 2/20 0.64
RAF1 P04049 2/20 0.64
MET P08581 1/20 0.64
SRC P12931 1/20 0.64
FLT1 P17948 1/20 0.64
BRAF P15056 2/20 0.63
MAPK14 Q16539 1/20 0.63
TNNI3K Q59H18 1/20 0.63
FLT3 P36888 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204091 0.89 KDR (0.89) KDRPDGFRACSF1RKITPDGFRB
SCHEMBL5202754 0.87 KDR (1.00) KDRPDGFRACSF1RKITPDGFRB
SCHEMBL5207985 0.87 KDR (0.81) KDRPDGFRACSF1RKITPDGFRB
SCHEMBL5204895 0.86 KDR (0.94) KDRPDGFRACSF1RKITPDGFRB
SCHEMBL5825916 0.86 KDR (0.78) KDRPDGFRACSF1RKITPDGFRB
SCHEMBL4468642 0.85 PDGFRA (0.73) KDRPDGFRAMET
Hydrochloric Acid SCHEMBL4474520 0.85 PDGFRA (0.71) KDRPDGFRAMET
SCHEMBL7480612 0.85 KDR (1.00) KDRPDGFRACSF1RKITPDGFRB
SCHEMBL5208273 0.84 KDR (0.76) KDRPDGFRACSF1RKITPDGFRB
SCHEMBL5202999 0.84 KDR (0.76) KDRPDGFRACSF1RKITPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
EP-1566379-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2005-08-24 EP disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 KDR 211/4885PDGFRA 372/4885CSF1R 88/4885
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same FLT3, TYRO3, ABL1 KDR 148/4885PDGFRA 229/4885CSF1R 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.